One-Year Follow-Up of Seroprevalence of SARS-CoV-2 Infection and Anxiety among Health Workers of a French Cancer Center: The PRO-SERO-COV Study

Brice Richez, Coralie Cantarel (), Françoise Durrieu, Isabelle Soubeyran, Julie Blanchi, Simon Pernot, Camille Chakiba Brugère, Guilhem Roubaud, Sophie Cousin, Gabriel Etienne, Anne Floquet, Florence Babre, Julie Rivalan, Caroline Lalet, Marine Narbonne, Yaniss Belaroussi, Carine Bellera and Simone Mathoulin-Pélissier
Additional contact information
Brice Richez: Department of Anesthesia—Intensive Care, Institut Bergonié, Comprehensive Cancer Center, F-33000 Bordeaux, France
Coralie Cantarel: Inserm CIC1401, Clinical and Epidemiological Research Unit, Institut Bergonié, Comprehensive Cancer Center, F-33000 Bordeaux, France
Françoise Durrieu: Department of Biopathology, Institut Bergonié, Comprehensive Cancer Center, F-33000 Bordeaux, France
Isabelle Soubeyran: Department of Biopathology, Institut Bergonié, Comprehensive Cancer Center, F-33000 Bordeaux, France
Julie Blanchi: Department of Biopathology, Institut Bergonié, Comprehensive Cancer Center, F-33000 Bordeaux, France
Simon Pernot: Department of Medical Oncology, Institut Bergonié, Comprehensive Cancer Center, F-33000 Bordeaux, France
Camille Chakiba Brugère: Department of Medical Oncology, Institut Bergonié, Comprehensive Cancer Center, F-33000 Bordeaux, France
Guilhem Roubaud: Department of Medical Oncology, Institut Bergonié, Comprehensive Cancer Center, F-33000 Bordeaux, France
Sophie Cousin: Department of Medical Oncology, Institut Bergonié, Comprehensive Cancer Center, F-33000 Bordeaux, France
Gabriel Etienne: Hematology Department, Institut Bergonié, Comprehensive Cancer Center, F-33000 Bordeaux, France
Anne Floquet: Department of Medical Oncology, Institut Bergonié, Comprehensive Cancer Center, F-33000 Bordeaux, France
Florence Babre: Department of Anesthesia—Intensive Care, Institut Bergonié, Comprehensive Cancer Center, F-33000 Bordeaux, France
Julie Rivalan: Department of Anesthesia—Intensive Care, Institut Bergonié, Comprehensive Cancer Center, F-33000 Bordeaux, France
Caroline Lalet: Inserm CIC1401, Clinical and Epidemiological Research Unit, Institut Bergonié, Comprehensive Cancer Center, F-33000 Bordeaux, France
Marine Narbonne: Department PRISME, Institut Bergonié, Comprehensive Cancer Center, F-33000 Bordeaux, France
Yaniss Belaroussi: Inserm CIC1401, Clinical and Epidemiological Research Unit, Institut Bergonié, Comprehensive Cancer Center, F-33000 Bordeaux, France
Carine Bellera: Inserm CIC1401, Clinical and Epidemiological Research Unit, Institut Bergonié, Comprehensive Cancer Center, F-33000 Bordeaux, France
Simone Mathoulin-Pélissier: Inserm CIC1401, Clinical and Epidemiological Research Unit, Institut Bergonié, Comprehensive Cancer Center, F-33000 Bordeaux, France

IJERPH, 2023, vol. 20, issue 11, 1-14

Abstract: Infection of SARS-CoV-2 among health workers (HWs) in contact with cancer patients has been a major issue since the beginning of the pandemic. We aimed to assess the serological immune status of SARS-CoV-2 infection among these HWs. A prospective cohort study was initiated in the comprehensive cancer center of the Nouvelle-Aquitaine region (NA, France). Volunteer HWs working on March 2020 without active infection or symptoms of COVID-19 completed a self-questionnaire and had a blood test at inclusion, at 3 and 12 months. Positive serological status of SARS-CoV-2 infection was defined by anti-nucleocapsid antibodies and/or IgG anti-spike antibodies, except at 12 months due to vaccine. Half of the HWs were included (N = 517) and 89% were followed for three months (N = 500) and one year (N = 462). Seroprevalence of SARS-CoV-2 infection was 3.5% (95% CI: 1.9–5.1), 6.2% (95% CI: 4.1–8.3), and 10% (95% CI: 7.2–12.7) on June–September 2020, September 2020–January 2021, and June–October 2021, respectively. At 12 months, 93.3% had detectable antibodies with 80% vaccinated in the first three months of vaccine availability. The COVID-19-free policy of the institution, respect for barrier gestures, high and early vaccination of HWs, and low prevalence of SARS-CoV-2 in NA may explain the low rate of seropositivity among the HWs of the Institut Bergonié.

Keywords: SARS-CoV-2; COVID-19; health workers; antibody; seroprevalence; cancer center; anxiety; vaccination hesitancy (search for similar items in EconPapers)
JEL-codes: I I1 I3 Q Q5 (search for similar items in EconPapers)
Date: 2023
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.mdpi.com/1660-4601/20/11/5949/pdf (application/pdf)
https://www.mdpi.com/1660-4601/20/11/5949/ (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:gam:jijerp:v:20:y:2023:i:11:p:5949-:d:1155294

Access Statistics for this article

IJERPH is currently edited by Ms. Jenna Liu

More articles in IJERPH from MDPI
Bibliographic data for series maintained by MDPI Indexing Manager ().